Cadrenal Therapeutics, Inc.
- Market cap
- $3.89M
- 52w range
- $0.97 - $14.64
- Beta
- 1.84
- Sector
- Healthcare
- Data quality
- 67/100
- Moat score
- 5/100
- Return on equity
- -275.2%
- Analyst target
- $14.00
- Target upside
- +1343.3%
- Analysts
- 3
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Valuation
Derived from filed metrics · Moderate confidence (67% of the inputs available)
Moat, fair value and rating computed by our valuation engine (ported from the original Python model).